- Home
- BRN vs SABS Comparison
BRN vs SABS Comparison
Compare BRN & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- SABS
- Stock Information
- Founded
- BRN 1956
- SABS 2014
- Country
- BRN United States
- SABS United States
- Employees
- BRN N/A
- SABS N/A
- Industry
- BRN Oil & Gas Production
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- BRN Energy
- SABS Health Care
- Exchange
- BRN Nasdaq
- SABS Nasdaq
- Market Cap
- BRN 23.7M
- SABS 23.9M
- IPO Year
- BRN N/A
- SABS N/A
- Fundamental
- Price
- BRN $1.74
- SABS $3.70
- Analyst Decision
- BRN
- SABS Strong Buy
- Analyst Count
- BRN 0
- SABS 5
- Target Price
- BRN N/A
- SABS $12.40
- AVG Volume (30 Days)
- BRN 19.4K
- SABS 78.4K
- Earning Date
- BRN 12-13-2024
- SABS 11-06-2024
- Dividend Yield
- BRN 3.49%
- SABS N/A
- EPS Growth
- BRN N/A
- SABS N/A
- EPS
- BRN N/A
- SABS N/A
- Revenue
- BRN $24,300,000.00
- SABS $1,512,723.00
- Revenue This Year
- BRN N/A
- SABS N/A
- Revenue Next Year
- BRN N/A
- SABS N/A
- P/E Ratio
- BRN N/A
- SABS N/A
- Revenue Growth
- BRN N/A
- SABS N/A
- 52 Week Low
- BRN $1.62
- SABS $2.16
- 52 Week High
- BRN $3.20
- SABS $9.72
- Technical
- Relative Strength Index (RSI)
- BRN 29.56
- SABS 57.82
- Support Level
- BRN $1.62
- SABS $3.17
- Resistance Level
- BRN $1.96
- SABS $4.37
- Average True Range (ATR)
- BRN 0.09
- SABS 0.45
- MACD
- BRN -0.01
- SABS -0.01
- Stochastic Oscillator
- BRN 24.39
- SABS 59.83
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.